Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

AUTOR(ES)

Moreland, Larry

FONTE

BioMed Central

RESUMO

Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide production. In animal models of arthritis, treatment with recombinant human IL-11 (rhIL-11) reduces both the level of synovitis and the histologic lesion scores in the joints.

Documentos Relacionados

• Hyoscine butylbromide for colorectal polyp detection: prospective, randomized, placebo-controlled trial
• Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial.
• A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]
• Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.
• A randomised, double‐blind, placebo‐controlled trial of a recombinant version of human α‐fetoprotein (MM‐093) in patients with active rheumatoid arthritis